Milestone Q2 2026 net loss $28.6M; CARDAMYST coverage jumps to ~50% of commercial lives

Milestone Pharmaceuticals Inc.

2026-Q2 EPS reported -$0.41 vs consensus -$0.20 ▼ miss (-106.1%)

Q2 2026 net loss of $28.6M ($0.21/share) vs $13.0M ($0.20/share) in Q2 2025.
Product revenue $0.6M in Q2; first sales from CARDAMYST launched mid-Feb 2026.
Cash, equivalents, short-term investments $170.6M as of June 30, 2026; runway into H2 2027.
CARDAMYST: >800 prescribers, >1,500 scripts filled; commercial coverage now ~50% via UnitedHealthcare.
Phase 3 ReVeRA-301 AFib-RVR trial sites activated; EMA decision on etripamil for PSVT expected H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.